JP7801217B2 - 肝虚血再灌流障害におけるヘパラン硫酸（ｈｓ）オリゴ糖の効果 - Google Patents

肝虚血再灌流障害におけるヘパラン硫酸（ｈｓ）オリゴ糖の効果

Info

Publication number
JP7801217B2
JP7801217B2 JP2022527682A JP2022527682A JP7801217B2 JP 7801217 B2 JP7801217 B2 JP 7801217B2 JP 2022527682 A JP2022527682 A JP 2022527682A JP 2022527682 A JP2022527682 A JP 2022527682A JP 7801217 B2 JP7801217 B2 JP 7801217B2
Authority
JP
Japan
Prior art keywords
mer
groups
compounds
glcns6s
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022527682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501568A5 (https=
JPWO2021097345A5 (https=
JP2023501568A (ja
Inventor
アーノルド カテリン
リウ ジエン
パウリンスキー ラファル
クーレイ ブライアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2023501568A publication Critical patent/JP2023501568A/ja
Publication of JP2023501568A5 publication Critical patent/JP2023501568A5/ja
Publication of JPWO2021097345A5 publication Critical patent/JPWO2021097345A5/ja
Application granted granted Critical
Publication of JP7801217B2 publication Critical patent/JP7801217B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2022527682A 2019-11-13 2020-11-13 肝虚血再灌流障害におけるヘパラン硫酸（ｈｓ）オリゴ糖の効果 Active JP7801217B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934845P 2019-11-13 2019-11-13
US62/934,845 2019-11-13
PCT/US2020/060581 WO2021097345A1 (en) 2019-11-13 2020-11-13 Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury

Publications (4)

Publication Number Publication Date
JP2023501568A JP2023501568A (ja) 2023-01-18
JP2023501568A5 JP2023501568A5 (https=) 2023-11-21
JPWO2021097345A5 JPWO2021097345A5 (https=) 2023-11-21
JP7801217B2 true JP7801217B2 (ja) 2026-01-16

Family

ID=75912907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022527682A Active JP7801217B2 (ja) 2019-11-13 2020-11-13 肝虚血再灌流障害におけるヘパラン硫酸（ｈｓ）オリゴ糖の効果

Country Status (5)

Country Link
US (1) US12569512B2 (https=)
EP (1) EP4041251A4 (https=)
JP (1) JP7801217B2 (https=)
CN (1) CN114980904A (https=)
WO (1) WO2021097345A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110446511B (zh) 2017-03-10 2024-04-02 北卡罗来纳大学查珀尔希尔分校 短效的基于肝素的抗凝血剂化合物和方法
WO2019010216A1 (en) 2017-07-03 2019-01-10 The University Of North Carolina At Chapel Hill ENZYMATIC SYNTHESIS OF HOMOGENEOUS CHONDROITIN SULFATE OLIGOSACCHARIDES
JP7495061B2 (ja) 2017-11-03 2024-06-04 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 抗炎症作用を有する硫酸化オリゴ糖
CN112437667B (zh) 2018-06-20 2024-05-28 北卡罗来纳大学查珀尔希尔分校 细胞保护方法和组合物
WO2021097345A1 (en) 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury
US20250019465A1 (en) * 2021-11-12 2025-01-16 The Board Of Regents Of The University Of Texas System Compositions and methods for rare heparan sulfate glycan-targeted cancer treatment
WO2024054682A2 (en) * 2022-09-09 2024-03-14 The University Of North Carolina At Chapel Hill Ultralow molecular weight heparin
CN116987212B (zh) * 2023-09-25 2023-12-26 山东大学 低分子量硫酸乙酰肝素及其衍生物和制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019090203A1 (en) 2017-11-03 2019-05-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1232939B (it) 1987-11-06 1992-03-10 Opocrin Spa Eparan solfato caratterizzato da elevata attivita' antitrombotica, elevata biodisponibilita', assenza di attivita' anticoagulante; suo processo di estrazione da organi e da tessuti e relative composizioni farmaceutiche
US4865870A (en) 1988-07-07 1989-09-12 Becton, Dickinson And Company Method for rendering a substrate surface antithrombogenic
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5378829A (en) 1990-04-23 1995-01-03 Akzo N.V. Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type
AU2561792A (en) 1991-09-06 1993-04-05 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
IT1260137B (it) 1992-04-17 1996-03-28 Alfa Wassermann Spa Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
JP3818676B2 (ja) 1994-07-22 2006-09-06 生化学工業株式会社 ヘパラン硫酸６−ｏ−硫酸基転移酵素
IT1271057B (it) 1994-11-04 1997-05-26 Inalco Spa Polisaccaridi aventi un elevato contenuto di acido iduronico
JP3672359B2 (ja) 1995-07-24 2005-07-20 生化学工業株式会社 ヘパラン硫酸 ２−ｏ−硫酸基転移酵素
JP3713276B2 (ja) * 1995-09-29 2005-11-09 バイオマリン ファーマシューティカル インコーポレイテッド 炎症反応の軽減のためのヘパリナーゼの使用
US5935824A (en) 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6861254B1 (en) 1997-10-24 2005-03-01 Massachusetts Institute Of Technology Heparan sulfate D-glucosaminyl 3-O-sulfotransferases, and uses therefor
US8088604B2 (en) 1998-04-02 2012-01-03 The Board Of Regents Of The University Of Oklahoma Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases
US7307159B2 (en) 2001-05-08 2007-12-11 The Board Of Regents Of The University Of Oklahoma Heparin/heparosan synthase from P. multocida and methods of making and using same
IL127851A0 (en) 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6255088B1 (en) 1999-05-11 2001-07-03 The Scripps Research Institute Enzymatic sulfation of biomolecules
US6977248B1 (en) 1999-08-25 2005-12-20 Massachusetts Institute Of Technology Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
EP2845596A3 (en) 2000-01-10 2015-07-15 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
US7101859B2 (en) 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
WO2002004471A1 (fr) 2000-07-07 2002-01-17 Seikagaku Corporation Fractions oligosaccharidiques d'acide hyaluronique et medicament les contenant
US8067196B2 (en) 2001-03-28 2011-11-29 Massachusetts Institute Of Technology 6-O sulfated polysaccharides and methods of preparation thereof
US7300922B2 (en) 2001-05-25 2007-11-27 Duke University Modulators of pharmacological agents
WO2003018598A2 (en) 2001-08-30 2003-03-06 University College Dublin Monosaccharide derivatives
WO2004005475A2 (en) 2002-07-05 2004-01-15 University Of North Carolina At Chapel Hill Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
WO2005014619A2 (en) 2003-03-28 2005-02-17 Thomas Jefferson University Heparin-binding peptides and uses thereof
US20040259142A1 (en) 2003-06-04 2004-12-23 Imperial College Innovations Limited Products and methods
ATE502062T1 (de) 2003-10-24 2011-04-15 3M Innovative Properties Co Wässrige dispersionen von polytetrafluorethylenteilchen
US7655445B2 (en) 2003-11-12 2010-02-02 Massachusetts Institute Of Technology Methods for synthesis of sulfated saccharides
US7619637B2 (en) 2004-04-09 2009-11-17 Samsung Electronics Co., Ltd. Systems and methods for improved gamut mapping from one image data set to another
WO2005118609A2 (en) 2004-05-26 2005-12-15 California Institute Of Technology Small molecule stimulators of neuronal growth
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
WO2006015171A2 (en) 2004-07-28 2006-02-09 The Texas A & M University System Use of glycosoaminoglycans for the prevention and treatment of sepsis
WO2006124801A2 (en) 2005-05-12 2006-11-23 The University Of North Carolina At Chapel Hill Enzymatic synthesis of sulfated polysaccharides
WO2007023867A1 (ja) 2005-08-24 2007-03-01 Seikagaku Corporation 新規コンドロイチン画分製造方法
CN101495517B (zh) 2006-05-25 2012-10-10 莫曼塔医药品有限公司 低分子量肝素及其用途
WO2009014715A2 (en) 2007-07-23 2009-01-29 The University Of North Carolina At Chapel Hill Enzymatic synthesis of sulfated polysaccharides without iduronic acid residues
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
WO2009079693A1 (en) 2007-12-21 2009-07-02 Glycan Biosciences Design and selection of medicaments that modulate the function and activity of interleukin 13
EP2364165B1 (en) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
CA2750188C (en) 2009-02-02 2016-11-29 Otsuka Chemical Co., Ltd. Low-molecular polysulfated hyaluronic acid derivative and compositions containing same
BRPI1010516A2 (pt) * 2009-04-09 2015-08-25 Univ North Carolina Métodos de tratamento de edema relacionados à isquemia-reperfusão
US20110054236A1 (en) 2009-08-25 2011-03-03 The Regents Of The University Of Michigan Compositions and methods for targeting tumors
EP2480237A1 (en) 2009-09-23 2012-08-01 Momenta Pharmaceuticals, Inc. Methods of treatment with a low molecular weight heparin composition
DK2646037T3 (en) 2010-12-01 2019-03-04 Univ Australian National use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis
US11203772B2 (en) 2010-12-23 2021-12-21 The University Of North Carolina At Chapel Hill Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins
TW201309305A (zh) 2011-02-22 2013-03-01 Rensselaer Polytech Inst 用於製造生物工程肝素之單一步驟肝素前體之ｎ－去乙醯化作用及解聚合作用
US8519189B2 (en) 2011-06-01 2013-08-27 University Of British Columbia Polymers for reversing heparin-based anticoagulation
CA2901225C (en) * 2013-03-08 2023-09-19 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
ES2924830T3 (es) 2013-06-17 2022-10-11 Univ North Carolina Chapel Hill Moléculas de heparina reversibles
CN110446511B (zh) * 2017-03-10 2024-04-02 北卡罗来纳大学查珀尔希尔分校 短效的基于肝素的抗凝血剂化合物和方法
WO2019010216A1 (en) 2017-07-03 2019-01-10 The University Of North Carolina At Chapel Hill ENZYMATIC SYNTHESIS OF HOMOGENEOUS CHONDROITIN SULFATE OLIGOSACCHARIDES
CN112437667B (zh) 2018-06-20 2024-05-28 北卡罗来纳大学查珀尔希尔分校 细胞保护方法和组合物
WO2021097345A1 (en) 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury
JP7670561B2 (ja) 2021-06-28 2025-04-30 日本航空電子工業株式会社 コネクタ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019090203A1 (en) 2017-11-03 2019-05-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The Journal of Clinical Investigation，2015年，125(2)，pp.539-550
Thromb. Haemost.，2007年，97，pp.81-87

Also Published As

Publication number Publication date
US12569512B2 (en) 2026-03-10
EP4041251A4 (en) 2023-11-29
WO2021097345A1 (en) 2021-05-20
JP2023501568A (ja) 2023-01-18
EP4041251A1 (en) 2022-08-17
CN114980904A (zh) 2022-08-30
US20220265699A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
JP7801217B2 (ja) 肝虚血再灌流障害におけるヘパラン硫酸（ｈｓ）オリゴ糖の効果
JP3286321B2 (ja) 新規なアミノステロール抗生物質
EP1809303B1 (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
JP7728547B2 (ja) 抗炎症作用を有する硫酸化オリゴ糖
CN112437667B (zh) 细胞保护方法和组合物
RU2675819C1 (ru) Производные полимиксина и их применение
KR100930982B1 (ko) 세균 감염 치료용 달바반신 조성물
Sappington et al. Ethyl pyruvate provides durable protection against inflammation-induced intestinal epithelial barrier dysfunction
JP2001503018A (ja) 新規なヘパリン結合ペプチド
Ding et al. Treatment with unfractionated heparin attenuates coagulation and inflammation in endotoxemic mice
CN117323438B (zh) 四面体框架核酸-姜黄素复合物在制备预防和/或治疗糖尿病性骨质疏松的药物中的用途
AU2010283614B2 (en) FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof
WO2025137542A1 (en) Use of heparan sulfate (hs) oligosaccharides in diseases
CN101203230A (zh) 用nod因子例如葡糖胺寡糖调节血管发生
CN1468104A (zh) 嘌呤活性和ains活性的结合在制备抗血栓或抗炎药中的应用
BRPI0715269A2 (pt) composto, sal do composto, composiÇço farmacÊutica, mÉtodo para a fabricaÇço de uma composiÇço farmacÊutica, uso de um composto e mÉtodo para o tratamento de uma disfunÇço na coagulaÇço sanguÍnea
Eckenhoff et al. Cardiac mitochondrial calcium content during fatal doxorubicin toxicity
JP6353849B2 (ja) Ｂａｃｅ−１の阻害剤としての糖樹状クラスター化合物
BR112019028134A2 (pt) peptídeo pró-fármaco com propriedades farmacêuticas
CN103443114A (zh) 激活fgf受体的3-o-烷基寡糖、其制备及其治疗用途
Gadi Activated protein C reverses epigenetically sustained p66Shc expression in plaque-associated macrophages in diabetes mellitus
CN119113082A (zh) 预防和/或减轻肝缺血再灌注损伤的多肽及其应用
CA2424926A1 (en) Low molecular serine protease inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals
HUP0600626A2 (en) New medical use of mononucleosides
WO2012045114A1 (en) Agents and methods for treating hematologic conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230110

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231113

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260105

R150 Certificate of patent or registration of utility model

Ref document number: 7801217

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150